Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

398 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
Valgimigli M, Frigoli E, Leonardi S, Vranckx P, Rothenbühler M, Tebaldi M, Varbella F, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andó G, Ferrario M, Limbruno U, Garbo R, Sganzerla P, Russo F, Nazzaro M, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Ferrante G, Santarelli A, Sardella G, de Cesare N, Tosi P, van 't Hof A, Omerovic E, Brugaletta S, Windecker S, Heg D, Jüni P; MATRIX Investigators. Valgimigli M, et al. Among authors: brugaletta s. Lancet. 2018 Sep 8;392(10150):835-848. doi: 10.1016/S0140-6736(18)31714-8. Epub 2018 Aug 25. Lancet. 2018. PMID: 30153988 Clinical Trial.
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.
Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabatè M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R; Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Valgimigli M, et al. Among authors: brugaletta s. Circulation. 2009 Jun 30;119(25):3215-22. doi: 10.1161/CIRCULATIONAHA.108.833236. Epub 2009 Jun 15. Circulation. 2009. PMID: 19528337 Clinical Trial.
Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy.
Campo G, Fileti L, de Cesare N, Meliga E, Furgieri A, Russo F, Colangelo S, Brugaletta S, Ferrari R, Valgimigli M; 3T/2R Investigators. Campo G, et al. Among authors: brugaletta s. J Am Coll Cardiol. 2010 Oct 26;56(18):1447-55. doi: 10.1016/j.jacc.2010.03.103. J Am Coll Cardiol. 2010. PMID: 20951320 Free article. Clinical Trial.
Rationale and design of the EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction.
Sabaté M, Cequier A, Iñiguez A, Serra A, Hernández-Antolín R, Mainar V, Valgimigli M, Tespili M, den Heijer P, Bethencourt A, Vázquez N, Brugaletta S, Backx B, Serruys P. Sabaté M, et al. Among authors: brugaletta s. EuroIntervention. 2011 Dec;7(8):977-84. doi: 10.4244/EIJV7I8A154. EuroIntervention. 2011. PMID: 22115622 Free article. Clinical Trial.
Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial.
Sabate M, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, Valgimigli M, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Gómez-Hospital JA, Baz JA, Martin-Yuste V, van Geuns RJ, Alfonso F, Bordes P, Tebaldi M, Masotti M, Silvestro A, Backx B, Brugaletta S, van Es GA, Serruys PW. Sabate M, et al. Among authors: brugaletta s. Lancet. 2012 Oct 27;380(9852):1482-90. doi: 10.1016/S0140-6736(12)61223-9. Epub 2012 Sep 3. Lancet. 2012. PMID: 22951305 Clinical Trial.
One-year head to head comparison of the neointimal response between sirolimus eluting stent with reservoir technology and everolimus eluting stent: an optical coherence tomography study.
Shiratori Y, Brugaletta S, Alvarez-Contreras L, Azpeitia Y, Ospino N, Gaido S, Delahanty A, Santos A, Martin-Yuste V, Masotti M, Serruys PW, Windecker S, Sabaté M. Shiratori Y, et al. Among authors: brugaletta s. Catheter Cardiovasc Interv. 2013 Oct 1;82(4):E428-36. doi: 10.1002/ccd.24897. Epub 2013 Mar 25. Catheter Cardiovasc Interv. 2013. PMID: 23441068 Clinical Trial.
Predictors and clinical implications of stent thrombosis in patients with ST-segment elevation myocardial infarction: Insights from the EXAMINATION trial.
Brugaletta S, Sabate M, Martin-Yuste V, Masotti M, Shiratori Y, Alvarez-Contreras L, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, Valgimigli M, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Gomez-Lara J, Backx B, Serruys PW. Brugaletta S, et al. Int J Cardiol. 2013 Oct 3;168(3):2632-6. doi: 10.1016/j.ijcard.2013.03.036. Epub 2013 Apr 8. Int J Cardiol. 2013. PMID: 23578890 Clinical Trial.
398 results